Compare UHT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHT | BWAY |
|---|---|---|
| Founded | 1986 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.2M | 450.8M |
| IPO Year | 1995 | N/A |
| Metric | UHT | BWAY |
|---|---|---|
| Price | $40.05 | $12.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 52.7K | ★ 169.7K |
| Earning Date | 04-27-2026 | 03-11-2026 |
| Dividend Yield | ★ 7.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | $2.12 | $301.23 |
| Revenue Next Year | $2.94 | $24.33 |
| P/E Ratio | ★ $31.34 | $81.98 |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.26 | $7.84 |
| 52 Week High | $44.70 | $26.63 |
| Indicator | UHT | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 29.70 |
| Support Level | $38.72 | $11.55 |
| Resistance Level | $41.64 | $13.63 |
| Average True Range (ATR) | 1.08 | 0.72 |
| MACD | -0.42 | 0.19 |
| Stochastic Oscillator | 11.22 | 17.62 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.